← Back to Search

Neuromodulation Device

Axonics SacRal NeuromodulaTIon System for Urinary Urgency Incontinence TreatmeNt (ARTISAN-SNM Trial)

Irvine, CA
N/A
Waitlist Available
Led By Howard Goldman, MD FACS
Research Sponsored by Axonics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group

Summary

The ARTISAN-SNM study is designed to evaluate the safety and effectiveness of the Axonics Sacral Neuromodulation System as an aid in the treatment of the symptoms of urinary urgency incontinence (UUI) in patients who have failed or could not tolerate more conservative treatments.

See full description
Eligible Conditions
  • Urge Incontinence
  • Urge Urinary Incontinence

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Proportion of Responders
Secondary study objectives
Daily Number of Urgency Leaks
ICIQ-OAB-qol
Voids

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment groupExperimental Treatment1 Intervention
Urinary Urgency Incontinence
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Axonics Sacral Neuromodulation System (SNM) System
2017
N/A
~130

Find a Location

Closest Location:Cleveland Clinic· Cleveland, OH· 127 miles

Who is running the clinical trial?

Axonics, Inc.Lead Sponsor
6 Previous Clinical Trials
688 Total Patients Enrolled
Axonics Modulation Technologies, Inc.Lead Sponsor
3 Previous Clinical Trials
383 Total Patients Enrolled
Howard Goldman, MD FACSPrincipal InvestigatorThe Cleveland Clinic
Felicia Lane, MDPrincipal InvestigatorUC Irvine Health
8 Previous Clinical Trials
386 Total Patients Enrolled
~15 spots leftby Mar 2026